NEW YORK – Quest Diagnostics confirmed it has been cleared in US District Court for the Central District of California Western Division of misappropriating trade secrets from Cedars-Sinai Medical Center in developing a serological test for irritable bowel syndrome.
A jury last week determined that Quest did not steal trade secrets from Cedars-Sinai or breach its contract with the hospital when it developed an IBS test similar to one developed by Cedars-Sinai researchers.